177 related articles for article (PubMed ID: 35561046)
1. gBOIN-ET: The generalized Bayesian optimal interval design for optimal dose-finding accounting for ordinal graded efficacy and toxicity in early clinical trials.
Takeda K; Morita S; Taguri M
Biom J; 2022 Oct; 64(7):1178-1191. PubMed ID: 35561046
[TBL] [Abstract][Full Text] [Related]
2. TITE-gBOIN-ET: Time-to-event generalized Bayesian optimal interval design to accelerate dose-finding accounting for ordinal graded efficacy and toxicity outcomes.
Takeda K; Yamaguchi Y; Taguri M; Morita S
Biom J; 2023 Oct; 65(7):e2200265. PubMed ID: 37309248
[TBL] [Abstract][Full Text] [Related]
3. TITE-gBOIN: Time-to-event Bayesian optimal interval design to accelerate dose-finding accounting for toxicity grades.
Takeda K; Xia Q; Liu S; Rong A
Pharm Stat; 2022 Mar; 21(2):496-506. PubMed ID: 34862715
[TBL] [Abstract][Full Text] [Related]
4. BOIN-ETC: A Bayesian optimal interval design considering efficacy and toxicity to identify the optimal dose combinations.
Kakizume T; Takeda K; Taguri M; Morita S
Stat Methods Med Res; 2024 Apr; 33(4):716-727. PubMed ID: 38444354
[TBL] [Abstract][Full Text] [Related]
5. A generalized Bayesian optimal interval design for dose optimization in immunotherapy.
Xia Q; Takeda K; Yamaguchi Y; Zhang J
Pharm Stat; 2024 Jan; ():. PubMed ID: 38295856
[TBL] [Abstract][Full Text] [Related]
6. BOIN-ET: Bayesian optimal interval design for dose finding based on both efficacy and toxicity outcomes.
Takeda K; Taguri M; Morita S
Pharm Stat; 2018 Jul; 17(4):383-395. PubMed ID: 29700965
[TBL] [Abstract][Full Text] [Related]
7. TITE-BOIN-ET: Time-to-event Bayesian optimal interval design to accelerate dose-finding based on both efficacy and toxicity outcomes.
Takeda K; Morita S; Taguri M
Pharm Stat; 2020 May; 19(3):335-349. PubMed ID: 31829517
[TBL] [Abstract][Full Text] [Related]
8. A Bayesian optimal interval design for dose optimization with a randomization scheme based on pharmacokinetics outcomes in oncology.
Takeda K; Zhu J; Li R; Yamaguchi Y
Pharm Stat; 2023; 22(6):1104-1115. PubMed ID: 37545018
[TBL] [Abstract][Full Text] [Related]
9. An adaptive gBOIN design with shrinkage boundaries for phase I dose-finding trials.
Mu R; Hu Z; Xu G; Pan H
BMC Med Res Methodol; 2021 Dec; 21(1):278. PubMed ID: 34895153
[TBL] [Abstract][Full Text] [Related]
10. Comparison Between Simultaneous and Sequential Utilization of Safety and Efficacy for Optimal Dose Determination in Bayesian Model-Assisted Designs.
Li R; Takeda K; Rong A
Ther Innov Regul Sci; 2023 Jul; 57(4):728-736. PubMed ID: 37087525
[TBL] [Abstract][Full Text] [Related]
11. Incorporating historical information to improve dose optimization design with toxicity and efficacy endpoints: iBOIN-ET.
Zhao Y; Liu R; Takeda K
Pharm Stat; 2023; 22(3):440-460. PubMed ID: 36514849
[TBL] [Abstract][Full Text] [Related]
12. Optimal biological dose selection in dose-finding trials with model-assisted designs based on efficacy and toxicity: a simulation study.
Yamaguchi Y; Takeda K; Yoshida S; Maruo K
J Biopharm Stat; 2024 May; 34(3):379-393. PubMed ID: 37114985
[TBL] [Abstract][Full Text] [Related]
13. Improving early phase oncology clinical trial design: The case for finding the optimal biological dose.
Phillips A; Mondal S
Pharm Stat; 2023; 22(4):739-747. PubMed ID: 36669771
[TBL] [Abstract][Full Text] [Related]
14. TEPI-2 and UBI: designs for optimal immuno-oncology and cell therapy dose finding with toxicity and efficacy.
Li P; Liu R; Lin J; Ji Y
J Biopharm Stat; 2020 Nov; 30(6):979-992. PubMed ID: 32951518
[TBL] [Abstract][Full Text] [Related]
15. [Introduction of Oncology Dose-Finding Trial Designs].
Takeda K
Gan To Kagaku Ryoho; 2022 Apr; 49(4):365-370. PubMed ID: 35444116
[TBL] [Abstract][Full Text] [Related]
16. STEIN: A simple toxicity and efficacy interval design for seamless phase I/II clinical trials.
Lin R; Yin G
Stat Med; 2017 Nov; 36(26):4106-4120. PubMed ID: 28786138
[TBL] [Abstract][Full Text] [Related]
17. A comparison of phase I dose-finding designs in clinical trials with monotonicity assumption violation.
Abbas R; Rossoni C; Jaki T; Paoletti X; Mozgunov P
Clin Trials; 2020 Oct; 17(5):522-534. PubMed ID: 32631095
[TBL] [Abstract][Full Text] [Related]
18. Adaptive design for identifying maximum tolerated dose early to accelerate dose-finding trial.
Kojima M
BMC Med Res Methodol; 2022 Apr; 22(1):97. PubMed ID: 35382745
[TBL] [Abstract][Full Text] [Related]
19. Implementing and assessing Bayesian response-adaptive randomisation for backfilling in dose-finding trials.
Pin L; Villar SS; Dehbi HM
Contemp Clin Trials; 2024 Jul; 142():107567. PubMed ID: 38729298
[TBL] [Abstract][Full Text] [Related]
20. An extended Bayesian semi-mechanistic dose-finding design for phase I oncology trials using pharmacokinetic and pharmacodynamic information.
Yang C; Li Y
Stat Med; 2024 Feb; 43(4):689-705. PubMed ID: 38110304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
